Transcription factor activity of the nuclear respiratory factor 1 protein (NRF1) is increased in breast cancer. Whether this gain of NRF1 activity is directly involved in breast cancer remains unknown. Herein, we report a novel oncogenic function of NRF1 supporting its causative role in breast cancer development and progression. The gain of NRF1 and/or treatment with 17β-estradiol (E2) produced heterogeneous breast cancer stem cells (BCSCs) composed of more than ten distinct cell sub-populations. 
ABSTRACT
Transcription factor activity of the nuclear respiratory factor 1 protein (NRF1) is increased in breast cancer. Whether this gain of NRF1 activity is directly involved in breast cancer remains unknown. Herein, we report a novel oncogenic function of NRF1 supporting its causative role in breast cancer development and progression. The gain of NRF1 and/or treatment with 17β-estradiol (E2) produced heterogeneous breast cancer stem cells (BCSCs) composed of more than ten distinct cell sub-populations. Flow sorting combined with confocal imaging of markers for pluripotency, epithelial mesenchymal transition (EMT), and BCSCs phenotypically confirmed that the subpopulations of BCSCs arise from cell re-programming. Thus, we determined the molecular actions of NRF1 on its target gene CXCR4 because of its known role in the acquisition of BCSCs through EMT. CXCR4 was activated by NRF1 in a redox dependent manner during malignant transformation. NRF1-induced BCSCs were able to form xenograft tumors in vivo, while inhibiting transcription of CXCR4 prevented xenograft tumor growth. Consistent with our observation of NRF1 driven breast tumorigenesis in the experimental model, higher levels of NRF1 protein expression were also found in human breast cancer tissue specimens. This highly novel role of NRF1 in the stochastic acquisition of BCSCs and their progression to a malignant phenotype may open an entirely new research direction targeting NRF1 signaling in invasive breast cancer. Additionally, the discovery of targeting transcriptional activation of CXCR4 to inhibit NRF1-induced oncogenic transformation provides a mechanistic explanation for estrogen-dependent breast carcinogenesis and opens the new avenues for mechanistic therapeutic strategy against breast cancer.
INTRODUCTION
Nuclear respiratory factor 1 (NRF1) is widely recognized for regulating genes encoding mitochondrial biogenesis 1 . Recent evidence also indicates that the NRF1 protein interacts with a broad spectrum of transcription factors; and its unique DNA binding recognition site is one of seven transcription factor binding sites most frequently found in the proximal promoters of ubiquitous genes [2] [3] [4] . NRF1 motif(s) are found on the promoters of genes regulating the cell cycle, chromatin structure, cell apoptosis, cell adhesion/invasion, DNA repair, DNA methylation and transcriptional repression signaling; and epithelial adherens junctions [2] [3] [4] . These findings suggest that NRF1 is a multifunctional protein with roles in diverse cellular functions. The actual role NRF1 plays in breast cancer remains the least studied of all transcription factors. Metaanalysis of 18 published breast cancer microarray data showed that NRF1 is elevated in high grade breast carcinomas 5 . Our findings were validated by a recent study using TGCI normal and breast tumor specimens in which it was shown that NRF1 activity was significantly higher in human breast cancers compared to adjacent surrounding control breast tissue 6 . Furthermore, we have also shown that reactive oxygen species (ROS)-mediated activation of NRF1 is critical for the growth of estrogen-induced breast cancer cells and estrogen-induced malignant breast cell transformation 7, 8 . Whether NRF1 contributes to estrogen carcinogenesis in breast cancer is not fully understood. Life time exposure to elevated levels of estrogen is a major risk factor for breast cancer 9 .
Estrogen is a breast carcinogen, however, the molecular mechanisms responsible for estrogen-induced breast tumor initiation remain poorly understood. Although several signaling pathways may be targeted by estrogen in human mammary epithelial cells (HMECs) during the induction of a pre-malignant phenotype, our focus is on the NRF1 signal transduction pathway because DNA sequence motifs bound by NRF1 positively correlate with the malignant progression of breast cancer 10 .
Despite tremendous progress in understanding breast cancer, gaps remain in our knowledge of the molecular basis underlying the aggressiveness of breast cancer.
Breast tumor-initiating cells (BTICs) or breast cancer stem cells (BCSCs) are considered to be responsible for estrogen-induced initiation and aggressive progression of breast tumors 11 . We have recently shown that activation of the NRF1 pathway may participate in the development of breast tumors however its contribution to the acquisition of cancer stem cells remains unexplored in breast cancer 7, 8 . This malignancy may occur via transformation of adult stem cells into cancer stem cells that give rise to the tumor. There are several key genes related to cell growth, cell transformation, cell adhesion/motility and tumor suppression that are regulated by NRF1 12 . Some of these genes, including CXCR4 are up-regulated by estrogen treatment. The contribution of CXCR4 to reprogramming breast cancer cells to cancer stem cells is of particular interest to our research on NRF1. CXCR4 has an established role in the acquisition of BCSCs through epithelial mesenchymal transition (EMT) 13, 14 . Thus, it is biologically plausible that high NRF1 activity in breast tissue increases susceptibility to estrogeninduced breast carcinogenesis via upregulation of the CXCR4 gene. This NRF1 regulated gene alone or in concert with others may contribute to the estrogen-induced malignant phenotype. The purpose of this study was to investigate whether NRF1 modulated CXCR4 expression drives estrogen-induced malignant transformation of breast epithelial cells to BCSCs; and whether this NRF1 protein activity plays a major role in breast cancer development and progression. Our findings demonstrate that overexpression of NRF1 combined with exposure to a carcinogenic dose of 17β-estradiol (E2) through regulating CXCR4 generated BTICs that formed tumors in vivo.
Further clinical validation of this finding may lead to new avenues for NRF1 targeted therapeutic strategy against breast cancer.
RESULTS
Normal breast epithelial cells acquire breast tumor initiating properties by a gain in NRF1 activity in conjunction with exposure to E2: We have shown that estrogeninduced malignant breast tumor formation is NRF1 dependent. It was therefore logical to test whether the combination of NRF1 overexpression along with a carcinogenic E2 treatment regimen could generate BTICs. We used a spontaneously immortalized human breast epithelial MCF-10A cell line, derived from breast tissue of a woman with fibrocystic disease that is phenotypically normal 16 . Estrogen receptor (ER) α protein is not detectable in these cells. We chose this well characterized MCF-10 cell line, because we have already shown that E2 or its hydroxy metabolite, 4-OH-E2, transforms MCF-10A cells 7 . Stable NRF1 overexpressing MCF10A cells, after treatment with a carcinogenic regimen of E2, were grown as mammospheres in B27 medium then flow cell sorted for the breast cancer stem cell signature CD24-/CD44+. MCF10A cells showed stable ectopic expression of NRF1 and dominant negative NRF1 confirmed by immunofluorescence detection and Western blot (Fig. 1A) . i) E2 treatment enhanced breast tumor-initiating (breast cancer stem) cell features: Flow cytometry analysis of normal breast epithelial MCF10A cells (wild-type or CMV vector) indicated two distinct cell subpopulations based on differences in the expression of CD24 and CD44 markers. As shown in Fig. 1B&C and Table 1, approximately 27.46% of wild-type MCF10A cells were positive for CD24 while a higher percentage of cells (~72.54%) were negative for both CD24 and CD44 markers. MCF10A cells exposed to the carcinogenic E2 treatment regimen showed a shift in the distribution of these molecular markers. Treatment with E2 resulted in 1.46% of the cell population to be CD24+ while 26.02% of these cells were CD24-/CD44+ (Fig. 1B&C and Table 1 ). These two molecular subtypes are typically found in human breast tumor-initiating cells or BCSCs 16 . Undifferentiated basal/mesenchymal cancer stem cells are considered to be CD24-/CD44+ cells whereas differentiated basal/epithelial cancer stem cells are CD24+/CD44+ 17 . Since our E2 treatment had no effect on the percentage of CD24-/CD44-cells, we infer that the CD24+ MCF10A cells gave rise to these two new phenotypes (CD24+/CD44+ and CD24+/CD44-) during estrogen-induced cell transformation.
ii) Ectopic expression of NRF1 in mammary epithelial cells enriched CD44(high)/CD24(low) progenitor subtype and increased E2-induced progenitor
subpopulations: E2 treatment increases NRF1 expression. 18 Recently we have shown that NRF1 expression was increased in MCF10A cells upon E2 exposure and estrogeninduced breast cancer cell growth was reduced by the inhibition of NRF1 expression. 7 Based on our previous studies, we determined whether NRF1 contributes to the generation of cancer stem cells during E2-induced cell transformation of breast epithelial cells. Stable NRF1 overexpression resulted in a low percentage of CD24+/CD44+ (2.36%) cells and a higher percentage expressing the CD24-/CD44+ (64%) subtype ( Fig. 1B&C and Table 1 ). MCF10A cells were sorted for a population of CD24− or low/CD44+ tumor-initiating cells because this subtype represents tumorinitiating properties in breast cancer. 17, 18 These CD24-/CD44+ cells (shown in bold in Table 1 ) were then treated with a carcinogenic regimen of E2 or 4-OHE2 and propagated as mammospheres for the following experimental groups: Wild-type (WT), vector, NRF1 overexpression, and dominant negative NRF1. Ectopic NRF1 expression changed the percentage of CD24+ and CD24-/CD44-subtypes in vector control MCF10A cells from 27.46% to 0.26% and 72.54% to 33%, respectively. These results suggest that both of these subpopulations were re-programmed to the CD24+/CD44+
and CD24-/CD44+ phenotypes.
Ectopic NRF1 expression in MCF10A cells when exposed to carcinogenic E2 treatments showed an increase in acquiring the CD24+/CD44+ subtype (2.36% in NRF1 treatment alone was enriched to 21.54% in NRF1+E2) ( Fig. 1B&C and Table 1 ). We also observed a decrease in CD24-/CD44+ subtype from 64% in NRF1 alone to 44.54% in NRF1+E2. Dominant negative (DN) inhibition of NRF1 completely suppressed the induction of CD44+ cells ( Figure 1B) . In summary, a gain in NRF1 expression and/or treatment with E2 led to reprogramming of normal breast epithelial cells to acquire the breast cancer stem cell signature CD24-/CD44+.
iii) Phenotypic characteristics of Estrogen-Induced Tumor Initiating Breast Cancer Cells:
Self-renewal capacity of BTICs expressing the breast cancer stem signature was determined by measuring colony formation which also included measurements of cell motility and invasion. BTICs generated by the gain of NRF1 alone showed anchorageindependent growth, migration, invasion, and formed mammospheres when compared to control (Figure 2 ). When these BTICs were further exposed to E2, we observed an increase across all of the same phenotypic properties. These phenotypes were not detectable in CD24-/CD44-MCF10A control cells. Suppression of NRF1 by DN NRF1 inhibited NRF1 and/or E2-induced anchorage-independent growth, invasion ( Fig.   2A&B ) and tumorosphere formation of BTICs (Fig. 2C) . We also observed that phosphorylation-deficient NRF1 mutants (mutation at amino acid residues 109 and 203 of the NRF1 protein sequence) suppressed the susceptibility of the BTICs to develop tumor spheroids when exposed to E2 (Fig. 2D ).
iv) NRF1 supports self-renewal of breast cancer stem cells. BCSCs are faced with apoptosis and senescence as a barrier to their self-renewal. The ability of BCSCs to evade apoptosis and senescence contributes to cell reprogramming and stem cell survival, and ultimately progression to a malignant phenotype. Based on this rationale, we investigated the contribution of NRF1 to proliferation, apoptosis, and senescence of BCSCs ( Fig. 2E-I ).
To examine whether NRF1 expression confers a growth advantage to BCSCs, we measured the proliferative capacity of BCSCs by assessing cell viability/metabolic activity through reduction of a tetrazolium dye (MTT), cell mass/ cell number by binding of the Sulforhodamine B (SRB) dye to basic amino acids of cellular proteins, and BrDU incorporation into newly synthesized DNA. All three methods showed significantly high proliferative capacity based on cell viability/metabolic activity/cell mass/ BrDU incorporation in NRF1 overexpressing BCSCs compared to CD24-/CD44-MCF10A cells ( Fig. 2E-G) . We further determined whether inhibition of NRF1 could reverse the growth advantage seen in BCSCs. As expected, the suppression of NRF1 inhibited the proliferative capacity of BCSCs.
The effect of NRF1 on apoptosis of BCSCs was determined by measuring Annexin V/PI staining via flow cytometry. In addition, we examined the effect of NRF1 on replicative senescence in BCSCs by measuring senescence-associated β-galactosidase (SA-β-gal) activity, a widely used marker of senescence.
To test that senescence was inhibited by E2 and/or NRF1, SA-β-gal activity was histochemically detected in BCSCs and vector control cells. Control vector cells were positively stained with SA-β-gal, and E2 treatment significantly reduced its staining.
NRF1 overexpressing BCSCs did not show any SA-β-gal staining in the presence or absence of E2 treatment. These findings indicate that NRF1 suppresses senescence in BCSCs, which happens to be a major barrier to cell reprogramming, and characteristic of stem cells (Fig. 2I ).
For apoptosis analysis, BCSCs were subjected to FACS analysis after FITC Annexin V (x-axis) and propidium iodide (PI: y-axis) staining. Dead cells stained positive for both FITC Annexin V and PI and these cells are lowest in NRF1+ (0.42%) compared to vector control (4%) (Fig. 2H) Results of the FACS studies for BCSC markers are shown in Figure 1D&E and Table 1 Fig 3C) . In summary, NRF1 seems to be critical for an EMT phenotype. NRF1 acts via loss of E-cadherin and gain of N-cadherin, and vimentin in BTIS cells.
One of the properties of mesenchymal BCSCs is that they can differentiate into various connective tissue cells. Therefore, we assessed multi-lineage differentiation potentials of NRF1 mesenchymal BCSCs. We found that NRF1-induced BTICs or
BCSCs differentiated into chondrocytes, neurons, and smooth muscle cells. (Fig. 4C&D ). NRF1 and NRF1+E2 BTIC clones demonstrated a significantly higher potential to close the wound 6 h after initiation of the wound healing assay compared to the vector clone (**P < 0.01 and *P < 0.05). Also, the NRF1 and NRF1+E2 BTIC clones possessed a higher migration capacity compared to vector clone with and without E2 treatment ( Fig. 4E-H ).
BCSCs are resistant to chemotherapy and hormonal therapy 19, 20 . Therefore, we assessed the effects of anti-estrogens -Fulvestrant and Tamoxifen We then focused our efforts on the regulation of the metastasis-related CXCR4 gene because it is associated with stem cell acquisition and aggressive growth of breast tumors 13, 14, 28 . Furthermore, CXCR4 has been reported to be up-regulated in breast tumors 29 .
i) Effect of estrogen and NRF1 on CXCR4 transcription: CXCR4 is a target of NRF1 that is upregulated in E2-treated MCF-7 cells 30 . Therefore, we determined if NRF1
regulates transcription of CXCR4 in BTICs. We first assessed the binding of NRF1 to the promoter of the CXCR4 gene by ChIP-qPCR. We discovered that NRF1 was bound to the promoter of CXCR4, confirming that its promoter contains the NRF1 DNA element(s) (Fig. 6A ). NRF1 binding to the CXCR4 promoter was inhibited by DN NRF1 (Fig. 6B) . Reporter assay showed an increased functional activity of the BNIP3 promoter in NRF1 overexpressing cells treated with E2, and this was decreased by DN NRF1 (Fig. 6C ). MCF10A cells treated with E2 showed an increase in the mRNA levels of CXCR4 compared to vehicle control cells (Fig. 6D ). Our findings were consistent with a previous report that showed at the molecular level, E2 and NRF1 regulate CXCR4 gene expression in MCF-7 cells 30, 31 . NRF1 overexpression also increased CXCR4 mRNA levels, which was reversed by DN NRF1. We also observed the up-regulation of CXCR4 proteins in NRF1+ BTIC and this effect was reversed by DN NRF1 (Fig. 6E ).
These findings provide a mechanistic explanation for activation of CXCR4 and corroborated our flow sorting data showing increased CXCR4 protein levels in NRF1
overexpressing BTIC/BCSC cells. vector containing CD44-CD24-cells did not produce tumors over time (Fig.4K ).
These findings together suggest that CXCR4 may play an important role in NRF1
and/or E2-induced breast tumorigenesis. . Our results showed that the expression of NANOG, OCT4, and SOX2 were increased by NRF1. The re-activation of embryonic transcription factors is necessary for the acquisition of BTICS or BCSCs.
DISCUSSION
Recent studies suggest that EMT contributes to the acquisition of cancer stem cell properties 12, 20 . From ChIP-chip, ChIP-PET, and ChIP-seq analysis, we know not only which genes display altered expression when NRF1 activity is modulated but also which genomic loci are physically occupied by NRF1 4, 5, 11, 34, 35 . NRF1 localizes to several thousand sites in the human genome and may occupy up to 15% of the promoter regions. The percentage of NRF1 promoter occupation seems to be dependent on cell type. Embryonic stem cells have been shown to have roughly 33% of all active genes bound by NRF1 within 1 kb of the transcriptional start site 34, 36 . The mechanism by which NRF1 drives breast cancer stem cell-specific expression of pluripotency TFs, OCT4, SOX2 and NANOG necessary for maintaining breast cancer cell stemness remains to be determined. Recently, it has been found that the SOX2 gene lies in an intron of a long multi-exon non-coding RNA SOX2 overlapping transcript (SOX2-OT). SOX2-OT has been reported to positively regulate the expression of SOX2 and OCT4; and these two TFs also regulate NANOG expression 37, 38 . Since the enrichment of H3K4ac together with H3K4me3 is more reflective of the EMT response pathway in the MDAMB231 cell line 41, 42 , it is possible that NRF1 dependent EMT gene(s) are regulated by epigenetic marks facilitated by acetylation and methylation of histone H3 lysines 4 and 56 (H3K4 and 56 ac and/or me3).
To understand the mechanistic aspects of the contribution of NRF1 in susceptibility to the breast carcinogenicity, we focused our efforts on NRF1 motif enriched CXCR4 gene, which is implicated in breast cancer. NRF1 is known to mediate the cellular response to oxidative stress by regulating the expression of genes involved in the cell cycle, DNA repair, cell apoptosis, and mitochondrial biogenesis. Some of the same CXCR4 signaling pathways that are sensitive to ROS levels and E2 are also directly regulated by NRF1 7 . Recently, CXCR4 has been shown to drive the metastatic phenotype in breast cancer through activation of MEK and PI3K pathways 13 . In this study, we observed that CXCR4 signaling pathway was not only activated by NRF1, but was also responsive to exposures to both E2 and ROS. The activation of NRF1 was studied in the context of the up-regulation of the CXCR4 gene involved in the development of E2-dependent breast cancer. This observation is consistent with our finding of PTEN oxidation, and with earlier reports suggesting that ROS could reversibly modify the redox state of specific cysteine residues in PTPs and make them inactive.
These findings have important implications for understanding the molecular mechanisms by which the redox sensitive molecules AKT or ERK may participate in E2 mediated signaling to NRF1. NRF1 was reported to be a substrate of AKT and activation of AKT controls translocation of NRF1 to the nucleus. This observation is based on a study in which the translocation of NRF1 to the nucleus occurred in PTEN deficient cells and was abrogated when the PI3K pathway was blocked, inactivating cells/mL and treated with or without E2 (100pg/mL) for 24 h at 37 °C in a 5% CO2 incubator. Methylthiazoletetrazolium (MTT) solution (5 mg/mL) was added to each well and incubated for 30 min at 37°C. Thereafter MTT solution was removed. After addition of 180μl of DMSO the plates were incubated for 15 min at 37°C to dissolve the formazan crystals. Absorbance readings of DMSO extracts were performed at 560 nm with reference of 690 nm using a Tecan Genios microplate reader (Crailsheim, Germany).
MATERIALS AND METHODS

Cell line and cell culture
Sulforhodamine B assay
The method of plating and incubation for SRB assay were identical to MTT assay. After 24h treatment with or without E2, MCF-10A, MCF-7 and MD-MB 231 cells were fixed with 50% trichloroacetic acid at 4°C (50 μL/well) for 1 h. The plate was washed with tap water for five times, dried and stained with SRB dye (0.057% in 1% acetic acid) for 30 min and subsequently washed with 1% acetic acid to remove the unbound dye. Plate was air-dried and bound protein stain was solubilised with 100 μL 10 mM Tris base. The absorbance was recorded at 540 nm using a Tecan Genios microplate reader (Crailsheim, Germany).
BrdU cell proliferation assay
Bromodeoxyuridine (BrdU) incorporation was determined as a biological indicator of DNA synthesis in MCF-10A, MCF-7 and MD-MB 231 cells treated with E2 (367.1 pm). Cells were grown (2500 cells per well) in 96-well plates were labelled with BrdU for 24 h. Afterwards, a colorimetric BrdU cell proliferation assay was performed according to the manufacturer's instructions (Roche, Branford, CT, USA) as described previously (Felty et al, 2005b) . Absorbance of the samples was measured in a Tecan Genios microplate reader at 450 nm (reference λ at 700 nm).
FITC Annexin V Apoptosis detection
MCF-10A, MCF7 and MDA-MB-231 cells were seeded in six-well plates in DMEM/F12 and cells were treated with serum free medium containing DMSO as a vehicle or E2 (367.1 pm), or hydrogen peroxide (H2O2) (or 600 μM). One group was treated with 5% FBS. Cell apoptosis was assessed by using FITC Annexin V Apoptosis Detection Kit I (BD Pharmingen) according to the manufacturer's protocol. Briefly, cells were washed with cold PBS and then resuspended in 1X binding buffer, and 100 µl of solution containing cells were stained with 5 µl Annexin V-FITC and 5 µl propidium iodide (PI). After incubation in the dark for 15 min, 100 µl of 1X binding buffer was added and cells were analyzed by Guava easyCyte using the CytoSoft software program according to the manufacturer's instructions.
Cell invasion assay
For the cell invasion assay, the single cells were obtained from the mammospheres at 15 days using 0.5% trypsine. Approximately, 5x103 cells/mL were plated in the top chamber of the transwell filter insert (8.0um) (Costar corning) with matrigel-coated (BD bioscience). Cells were suspended in serum free medium and plated onto the upper chamber of transwell insert; 10% FBS medium was added to the lower chamber as a chemoattractant. After 24h incubation, invaded cells were stained with 0.2% crystal violet and images were acquired by microscope. The cells those did not invade, were removed by cotton swab. Invasive cells were counted and scored in triplicate (lower chamber).
Colony formation assay
Single cells were obtained from the mammospheres using 0.5%trypsine and these cells were seeded on top of soft agar (0.3%) with a bottom layer of 0.7% agar in DMEM/F12 in six-well plates and maintained in complete medium for 14 days. Cells were treated with DMSO as a vehicle or E2 (367.1 pM). After 14 days most of the colonies had expanded to more than 50 cells, the cells were washed with PBS, fixed in methanol for 15 min and stained with 0.005% crystal violet crystal violet for 15 min. The plates were then photographed, and the colonies were counted. At least three independent experiments were carried out for each assay.
Mammospheroid assay
The MCF-10A, MCF7 and MDA-MB-231 cells were suspended in serum-free DMEM/F12 (1:1) culture medium supplemented with B27. For mamospheroid formation, approximately 100-150 cells per well were seeded in an ultra-low attachment 96-well plate (Corning Inc, Lowell, MA). The effect of carcinogenic regime, estrogen (E2) was evaluated by treating E2 (100 pg/mL) on the day of seeding cells. Mamospheroids were grown for 27 days in liquid culture. A total of 15 spheroids with a minimum diameter of 50 mm were counted in each experimental group. Data were analyzed by ANOVA; Tukey HSD test for multiple comparisons.
Immunofluorescence staining, FACS assay, Immunoblotting of cells from mammospheroids
The single cells were obtained from the mammospheres using 0.5%trypsine and these cells were seeded on the wells of eight chambered slides (Nunc™ Lab-Tek™ II Chamber Slide™ System, ThermoFisher Scientific, cat#154534) with or without treatment of E2 (100 pg/mL) for 24 hrs. The cells were seeded in 6 well plate(USA Sicientifc Inc, CC7682-7506 ) for FACS assay and were seeded in tissue culture dish (CytoOne 100 x 20 mm, USA Sicientifc Inc, cat# CC7682-3394) for immunoblotting with or without treatment of E2 (100 pg/mL) for 24 hrs. The rabbit monoclonal antibody Nanog (D73G4, Cell Signaling Technology, Inc. cat #4903) was also used for Immunofluorescence, FACS assay, Immunoblotting with Sox2 and Oct4.
Immunofluorescence staining of mammospheroids
For immunofluorescence of spheroids, approximately 100 spheres were fixed with 4% paraformaldehyde in 1% Triton X-100, washed in PBS, serially dehydrated in methanol (25%, 50%, 75%, 95% & 100%). Then spheroids were rehydrated in descending percentage of methanol and washed in PBS. Spheroids were incubated in 3% normal goat serum (Vector Lab, Burlingame, CA) at 4 °C for 24 h and washed in PBS with 0.5% Tween 20 (PBST). Next, spheroids were incubated with primary antibodies anti-Sox-2 (Santa Cruz Biotechnology Y-17, SC-17320), and anti-Oct-4 (Cell Signaling Technology, 2750S) for 48 h at 4 °C, washed in PBST and incubated with anti-rabbitIgG Alexa Fluor® 546 for Oct-4 and anti-goat-IgG Alexa Fluor® 488 for Sox-2. Spheres were mounted in chamber slides and fluorescence staining analyzed. All samples were analyzed using a Nikon C1 laser scanning confocal microscope.
Cell differentiation
The single cells were obtained from the mammospheres (3 days old in B27 plus DMEMF12 media) of NRF1+ MCF10A clone and vector MCF10A using 0.5%trypsine and these cells were grown for 5 days in culture media (DMEMF12 plus 5% FBS). For differentiation, both, NRF1+ MCF10A clone and vector MCF10A were maintained in chondrocyte differentiation medium (cat #411D-250 Sigma) for 28 days. The NRF1+ MCF10A clone and vector MCF10A were cultured in either SMGS plus DMEM-F12 or neurobasal media plus nerve growth factor-7S (Sigma), Glutamax, and N2 supplement for a total of 28 days. Cells were grown in LabTek(R) II 8 chambered #1.5 German coverglass system, NUNC (Thermo Fisher Scientific Inc.). We determined cell differentiation of NRF1+ MCF10A clone at 28 days with staining of Alician blue; α-smooth muscle actin (smooth muscle marker); and β-tubulin III (neuron marker). Nuclei were counterstained with DRAQ5® (Cell Signaling). Vector did not show any differentiation to other cells.
Immunofluorescence and Immunoblot detection of Epithelial-Mesenchymal Transition (EMT) markers
The NRF1MCF10A clone, vector MCF10A, NRF1 MDA-MB231, vector MDA-MB231 cells were grown as mammospheres for three days in DMEM-F12 media with B27® serum-free supplement in ultra-low attachment plates. The single cells were obtained from the mammospheres using 0.5%trypsine and these cells were seeded on the wells of eight chambered slides (Nunc™ Lab-Tek™ II Chamber Slide™ System, ThermoFisher Scientific, cat#154534) with or without treatment of E2 (100 pg/mL) for 24 hrs. The cells were fixed with methanol and incubated at −20°C for 15 min. Immunofluorescence staining was performed according to standard procedures. The single cells were also seeded in tissue culture dish (CytoOne 100 x 20 mm, USA Sicientifc Inc, cat# CC7682-3394) for immunoblotting with or without treatment of E2 (100 pg/mL) for 24 hrs. The EMT markers, E cadherin (Sc-9989, Santa Cruz Biotechnology) N-cadherin (sc-7939, H-63, Santa Cruz Biotechnology), and Vimentin (AF2105, R&D Systems, Inc.) were used for Immunofluorescence and Immunoblot assays.
Fluorescence-Activated Cell Sorting (FACS) of CD44+/CD24+/CD133+/ALDH1+ Cells and tumorigenic spheroid formation assay
Cells were grown to 70-80% confluence and then trypsinised and washed with sorting buffer (1 × PBS, 5% FCS). The cells were resuspended with 100 μL sorting buffer and incubated with 15-20 μL anti-CD24-FITC, anti-CD44-PE, anti-CD133-APC and anti-ALDH1-QDot605, antibodies for 30 min at ice. The cells were washed and resuspended in 500 μL of sorting buffer and sorted using flow cytometry FACSAria IIu system (BD Biosciences). The sorted cells were suspended in serum-free DMEM/F12 (1:1) culture medium supplemented with B27. For tumorigenic spheroid formation, approximately 100 cells per well were seeded in an ultra-low attachment 96-well plate (Corning Inc, Lowell, MA). The tumorigenic spheroids were photographed with the HoloMonitoring and confocal microscopy as live images.
Cell migration assay
Cells were cultured in 6-well plates and a sterile plastic 1 mL micropipette tip was used to scratch in the middle area of the well as a line. Then cells were incubated in growth medium for 48 h. The scoring wounds were photographed with the HoloMonitoring and confocal microscopy as live images.
Detection of senescent cells
The Senescence β-Galactosidase Staining Kit (9860, Cell Signaling Technology, Inc.) was used which provided the reagents needed to detect β-galactosidase activity, a known characteristic of senescent cells of spheroids. Single cells were obtained from the spheroids using 0.5%trypsine and these cells were seeded on the wells of eight chambered slides (Nunc™ Lab-Tek™ II Chamber Slide™ System, ThermoFisher Scientific, cat#154534) for detection of blue colored beta-galactosidase activity as a characterize senescent cells. The cells were photographed with a compound optical microscopy (Fisher Scientific).
Determination of Reactive Oxygen Species (ROS)
Single cells were obtained from the spheroids using 0.5%trypsine and these cells were seeded on the wells of eight chambered slides (Nunc™ Lab-Tek™ II Chamber Slide™ System, ThermoFisher Scientific, cat#154534) for detection of ROS. The cells were serum starved for 48 h and pretreated with 10 μm of 2′, 7′-dichlorofluorescein-diacetate (DCFH-DA) (Molecular Probes, Eugene, OR, USA) for 20 min followed by treatment with E2. 2′, 7′-Dichlorofluorescein-diacetate is a non-fluorescent cell-permeable compound, which is acted upon by endogenous esterase that remove the acetate groups generating DCFH. In the presence of intracellular ROS, DCFH is rapidly oxidised to the highly fluorescent 2′, 7′-dichlorofluorescein (DCF). The oxidative products were measured with a Tecan Genios microplate reader (Morrisville, NC, USA) using 485 and 535 nm excitation and emission filters, respectively, as previously described by Felty et al (2005a) . Reactive oxygen species was also determined by a confocal microscopy.
Drug registrant characteristic of mammospheres
The MCF-10A, MCF7 (Estrogen/ER+ Progesterone/PR+ Human Epidermal growth factor Receptor 2/HER2-) and MDA-MB-231(ER-PR-HER2-) cells were suspended in serum-free DMEM/F12 (1:1) culture medium supplemented with B27. One hundred cells per well were seeded in an ultra-low attachment 96-well plate (Corning Inc, Lowell, MA). The breast cancer chemo therapeutic drug registrant characteristic of mammospheres were evaluated by treating Fulvestrant (5µM) (I4409, Sigma-Aldrich), Tamoxifen (10µM) (T5648, Sigma-Aldrich) and Paclitaxel, (50µM, 100µM) (T7402, Sigma-Aldrich) with or without E2 (100 pg/mL) on the day of seeding cells. The mammospheres were photomicrographed and analyzed at day 7 and 10.
LentiORF -CDKN2A assays CCSB-Broad LentiORF -CDKN2A pLX304-Blast-V5 Clone (cat# OHS6085-213583115) and corresponding empty vector were purchased from Dharmacon, a Horizon Discovery Group Co. Stable transduction of cells were carried out in a subconfluent MCF-10A cell population using Precision LentiORF Transduction Starter Kit (OHS5835, Dharmacon). Blasticidin S (100 μg/mL) was used for stable clone selection. The cells were suspended in serum-free DMEM/F12 (1:1) culture medium supplemented with B27 in an ultra-low attachment 96-well plate. The wells were photomicrographed at 5 and 10 days for MacroH2A1shRNA and 4, 8, and 16 days for LentiORF -CDKN2A studies. The wells were treated with vehicle [dimethyl sulfoxide (DMSO)] or E2 (100 pg/mL).
Analysis of NRF1 protein expression in human breast cancer tissue arrays
NRF1 protein expression in breast tumor tissueDW and normal breast tissue arrays (US Biomax) was measured using confocal microscopy and dual immunofluorescence staining of the with NRF1 specific antibodies (Rockland Immunochemicals Inc) paired together with Texas Red-conjugated secondary antibodies. Expression was scored as low (<the median intensity value), and high (>the median intensity value) levels per cancer cells based on immunofluorescence tissue staining intensity.
Immunofluorescence, Immunoblot studies for CXCR4
The MCF10A wild type, vector, NRF1 and dominant negative (DN) NRF1 cells were seeded on the wells of eight chambered slides (Nunc™ Lab-Tek™ II Chamber Slide™ System, ThermoFisher Scientific, cat#154534) with or without treatment of E2 (100 pg/mL) for 24 hrs. The CXCR4 (cat# sc-9046, H-118, Santa Cruz Biotechnology, Inc.), was used for immunofluorescence and immunoblot studies. The ALDH1 (cat # sc-22589, L-15, Santa Cruz Biotechnology, Inc.) and β-actin (13E5, rabbit mAb #4970, Cell Signaling Technology, Inc) antibodies were used for immunoblot study.
CXCR4 RNA interference on tumorsphere formation
For CXCR4 RNA interference (RNAi) studies, MCF10A wild type and NRF1 cells were cultured in 6-well plates to 60% confluency. Transfection was performed using FuGENE 6 (Roche) according to the manufacturer's protocol. The Accell CXCR4 siRNA (CAT# A-005139-14-0005 NM_001008540, Dharmacon) and Accell Human Control siRNA KitRed (K-005000-R1-01 Dharmacon, a Horizon Discovery Group Co.) were used for transfection the cells. Then the cells were suspended in serum-free DMEM/F12 (1:1) culture medium supplemented with B27 in an ultra-low attachment 96-well plate (Corning Inc, Lowell, MA) with or without treatment of E2 (100 pg/mL) for 3 days.The live cells images were captured by holographic live imagining system with HoloMonitor microscopy.
In vivo tumorigenesis in immunodeficient mice
We prepared the cell suspensions for transplantation as follows: Approximately 80% confluence, CD24-44+133+ALDH+ MCF-10A stem cells were washed twice with phosphate buffered saline (PBS) and treated with 0.25% trypsin-EDTA solution (Life Technologies) for detachment from cell culture dishes. The CD24-44+133+ALDH+ MCF-10A stem cells of different groups namely vector plus E2 (100 pg/mL), NRF1, NRF1 plus E2 (100 pg/mL), NRF1 plus E2 (100 pg/mL) plus control CXCR4, NRF1 plus E2 (100 pg/mL) plus siRNA CXCR4, NRF1 plus E2 (100 pg/mL) plus vector PARK2, and NRF1 plus E2 (100 pg/mL) plus ORF-PARK2 (GE Healthcare Dharmacon Inc OHS5836-EG5071, Precision LentiORF PARK2 Viral Particle Starter Kit, OHS5900-202625703 -PLOHS_100070632 ) were counted (1x10 3 ) and prepared in 100 μl of a 1:1 (v/v) mixture of cell culture medium and Matrigel (product #354234, BD Biosciences, San Jose, CA) for transplantation.
We performed the tumorigenicity test with immunodeficient female NOD/SCID mice (Jackson Laboratory, Bar Harbor, ME, USA) as follows: The mice were maintained in the animal research facility of Miami VA Healthcare System (1201 N.W. 16th Street, Miami, Florida) and were used for in vivo tumorigenicity studies. Prepared cell suspensions were injected using 1 ml syringes with a 25 G needle (Terumo) into mammary fat pads of 8-week-old mice (n = 5). The mice were palpated weekly for 6 weeks to observe nodule formation at the injection site. The successive engraftment was determined according to progressive nodule growth at the injection site. Mice were humane euthanized and sacrificed at 42 days (6 weeks). The tumors were weighted with a digital balance. The protocol of the present study was reviewed beforehand and approved by the Institutional Animal Care and Use Committee (IACUC) of Miami VA Healthcare System. All animal experiments were performed according to the Ethical Guidelines for Animal Experimentation from the VA IACUC. All animals were sacrificed under humane euthanasia with Carbon dioxide (CO2) inhalation and all efforts were made to minimize suffering. We prepared the engrafted tumors for histological analysis as follows: The tumors were isolated and fixed with 10% neutral buffered formalin (Wako). The paraffin-embedded sections were investigated by hematoxylin and eosin (H&E) stain for histological analysis.
Chromatin Immunoprecipitation (ChIP) qPCR assay to analyze NRF-1 binding to the promoters of CXCR4 genes
Chromatin immunoprecipitation assays (ChIP) were carried out with Epitech Chip qPCR primer assay (Qiagen, USA ). The MCF10A cells of vector, NRF1, dominant negative for NRF1(DN NRF1) were treated with or without E2 (100 pg/mL), for 24 h and analysed by ChIP assay using the anti-NRF1 antibody. CXCR4 promoter region (-109bp to -98 bp) in the NRF1 precipitated chromatin was amplified by real-time PCR using Epitech Chip qPCR primer assay for human CXCR4 NM_001008540.1 (-)03Kb Cat # GPH1021572(-)03A and Epitech chip one day kit according to manufacturer (Qiagen Science Inc.) instructions. Chromatin immunoprecipitation qPCR results were calculated using the ΔΔ Ct method.
Luciferase reporter assay for active CXCR4 gene promoter A total of 2 × 10 5 MCF10A cells of each group namely vector, NRF1, DN NRF1 were seeded in each well of a 6-well dish and transfected with desired plasmids using Lipofectamine 2000 reagent (Invitrogen). Cells were treated with DMSO or E2 (100 pg/mL). The assays were performed with CXCR4 luciferase reporter (cat# S712478, pLightSwitch_Prom, Switch Gear Genomics Inc) using light switch luciferase assay reagent (cat# LS010 Switch Gear Genomics Inc) of manufacturer. The cells were harvested after 24 h. Each data point obtained is the mean of three independent experiments.
Real-time qRT-PCR analysis for detection of CXCR4mRNA levels
Total RNAs were isolated with TRIzol reagent (Life Technologies, Grand Island, NY, USA) from MCF10A cells of each group namely vector, NRF1+, NRF1-(dominant negative for NRF1) exposed to DMSO or E2 (100 pg/mL). RNA sample was reversetranscribed into cDNA using the RT2 First Strand Kit from SuperArray Bioscience Corporation, Qiagen (Frederick, MD) according to the manufacturer's protocol. The polymerase chain reaction (PCR) reactions using cDNA were performed in a Applied Biosystems 7300 Real-Time PCR System using RT2 SYBR Green/ROX qPCR Master Mix and the manufacturer's thermal cycler protocol with 2 primers (Catalog no. (Fig. 4A&B) . C-J) Phenotypic characteristics of CD44+CD49f+ALDH+CXCR4+NRF1+ BCSCs subtype assessed by live imaging of tumorosphere formation, the migration and proliferation potential, and xenograft tumor growth assays; Large tumor spheroids were observed by HoloMonitoring (C) and confocal microscopy ( D) as live images of NRF1 and NRF1+E2 BTIC clones compared to the vector control did not form tumor spheroids at 5 and 15 days. E and F) This BCSCs clone demonstrated a significantly higher potential to close the wound 6 h after initiation of the wound healing assay compared to the vector clone (**P < 0.01 and *P < 0.05) and higher migration capacity compared to vector clone with and without E2 treatment (E-H). Table 1 Stochastic generation of different cell subpopulations of BCSCs separated by flow sorting by the CD24−CD44+ and CD49f, ALDH1, EPCAM, CD133, CXCR4 and NRF1 phenotypes. E2, NRF1+E2 and NRF1 transformed breast epithelial MCF10A cells were immunostained with CD24 and CD44 antibodies, and subsequently with CD49F, ALDH1, EPCAM, CD133, and CXCR4. The cell subpopulations defined by the CD24−CD44+ and other antigens phenotypes were separated by fluorescence-activated cell sorting (FACS). The percentages shown in the table show the representation of the cell subpopulations in the total transformed by E2 and/or NRF1 or parental cell population. 
